WA3-1
Eleven-residue anticoagulant + thrombolytic peptide from Whitmania pigra alcalase hydrolysate — Ren 2016 documents activity in aPTT, PT, and TT assays with thrombolytic effect.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Eleven-residue anticoagulant + thrombolytic peptide from Whitmania pigra alcalase hydrolysate — Ren 2016 documents activity in aPTT, PT, and TT assays with thrombolytic effect.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
WA3-1's in vitro anticoagulant + thrombolytic dual activity does NOT establish clinical efficacy. No FDA-approved derivative exists; W. pigra is a non-hematophagous TCM leech, not the FDA-cleared K040187 medicinal leech.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 1,422 Da
- Source species
- Whitmania pigra
- Discovered
- 2016 · Ren Y et al.
Biological Targets
- → aPTT-PT-TT triple-pathway prolongation
- → thrombolytic activity
Key Citations
- Ren Y et al. (2016), Amino Acids · PMID 27487778
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.